Fresh from a European cancer conference that was all about antibody-drug conjugates (ADCs), GSK has turned to French biotech ...

London: GSK plc and Syndivia, a private biotechnology company focused on next-generation ADCs, have announced an agreement ...

--GSK has lately posted lower vaccine sales in China and the U.S., and faces pressure to show that its pipeline includes new blockbuster drugs to counter concerns about that slowdown, AJ Bell ...

GSK has acquired the rights to Syndivia’s preclinical antibody drug conjugate (ADC), which is in development for prostate ...

The approval is based on data from a Phase III trial evaluating patients who had received two or more previous treatments.

The Food and Drug Administration’s approval of the cancer drug Blenrep late Thursday offered some vindication for GSK, which ...

US regulators approved GSK Plc’s blood cancer drug, a decision that will allow the company to bring the medicine back to the ...

GSK plc ( NYSE: GSK) and Syndivia on Monday announced an agreement granting GSK exclusive worldwide rights to develop and ...

GSK (LSE:GSK) has delivered share price gains of 9% over the past month and 16% in the past 3 months, reflecting steady ...

GSK has boosted its pipeline of antibody-drug conjugates for cancer, licensing a prostate cancer candidate from Syndivia in a ...

The new approval completes a surprise turnaround for Blenrep, which was initially cleared in 2020 but pulled from the market ...

GSK is set to acquire the exclusive rights for Syndivia’s preclinical antibody-drug conjugate (ADC), which is currently in ...